Menu Search
Equities

RemeGen Co Ltd

688331:SHH

RemeGen Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)25.50
  • Today's Change-9.93 / -28.03%
  • Shares traded2.76m
  • 1 Year change-62.64%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year RemeGen Co Ltd had net income fall 51.30% from a loss of 998.83m to a larger loss of 1.51bn despite a 40.26% increase in revenues from 772.11m to 1.08bn. An increase in the selling, general and administrative costs as a percentage of sales from 89.01% to 95.63% was a component in the falling net income despite rising revenues.
Gross margin78.65%
Net profit margin-101.95%
Operating margin-100.67%
Return on assets-27.65%
Return on equity-49.08%
Return on investment-36.21%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at RemeGen Co Ltd fell by 1.34bn. Cash Flow from Financing totalled 978.31m or 90.34% of revenues. In addition the company used 1.50bn for operations while cash used for investing totalled 816.66m.
Cash flow per share--
Price/Cash flow per share--
Book value per share4.35
Tangible book value per share4.09
More ▼

Balance sheet in CNYView more

RemeGen Co Ltd has a Debt to Total Capital ratio of 51.67%, a higher figure than the previous year's 18.03%.
Current ratio1.36
Quick ratio0.9558
Total debt/total equity1.07
Total debt/total capital0.5167
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.